Allo-HSCT: Unrelated, Haploidentical Donations May Yield Similar Outcomes
No differences were noted in rates of grade 2 to 4 acute graft-versus-host disease, non-relapse mortality, or relapse risk.
Hematopoietic Stem Cell Transplantation
Patient-Reported Outcomes and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation
Researchers sought to find whether there was a relationship between patient-reported outcomes and overall survival after hematopoietic stem cell transplantation.
Post-Transplant Carfilzomib, Lenalidomide, and Dexamethasone May Be New Standard of Care in Multiple Myeloma
Researchers sought to determine whether post-transplant carfilzomib, lenalidomide, and dexamethasone would have superior PFS in patients with multiple myeloma.
Varicella-Zoster Vaccination After Allogeneic Stem Cell Transplantation
Researchers sought to determine whether varicella-zoster virus vaccination with a recombinant vaccine would show results in patients who underwent HSCT.
Leukocyte-Endothelial Interactions May Be Marker for Outcomes After HCT
Researchers sought to determine whether leukocyte A&R would be linked with cancer relapse and survival after hematopoietic cell transplant.
Relapse Risk Lower With Double CBT Than With Matched Sibling or Unrelated Transplant
There was no significant difference in transplant-related mortality or overall survival.
Validation of Nursing Skills Improves Central Line Infection Rates on HSCT Unit
A project to reverse an increase in CLABSIs on an HSCT inpatient unit and its ongoing impact were described at the Annual ONS Congress.
Delays in Initiation of Revaccination in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant
Researchers sought to determine the effect of transplant-related complications and socioeconomic factors on revaccination schedule adherence among pediatric patients following allo-HSCT.
Mesenchymal Stromal Cells Improve Response to Second-Line aGVHD Therapy
Researchers sought to determine whether adding MSC to basiliximab and a calcineurin inhibitor would improve outcomes in patients with aGVHD after HSCT.
Omidubicel May Provide Long-Term Benefits With Allogeneic Transplantation for Hematologic Malignancies
Researchers sought to determine whether there were long-term benefits for patients with hematologic malignancies treated with allo-HSCT and omidubicel.
- Loading...
Loading...
Next post in Tandem Meetings 2022
Loading... 
Loading...